BRIDGEWATER, N.J., June 7, 2023 /PRNewswire/ -- Insmed Incorporated (Nasdaq:INSM), a global biopharmaceutical company on a mission to transform the lives of patients with serious and rare diseases, today announced that management will present in a fireside chat at the Goldman Sachs 44th Annual Global Healthcare Conference in Dana Point, CA, on Wednesday, June 14, 2023 at 1:20 p.m. PT (4:20 p.m. ET).
The fireside chat will be webcast live and can be accessed by visiting the investor relations section of the Company's website at www.insmed.com. The webcast will be archived for a period of 30 days following the conclusion of the live event.
About Insmed
Insmed Incorporated is a global biopharmaceutical company on a mission to transform the lives of patients with serious and rare diseases. Insmed's first commercial product is a first-in-disease therapy approved in the United States, Europe, and Japan to treat a chronic, debilitating lung disease. The Company is also progressing a robust pipeline of investigational therapies targeting areas of serious unmet need, including neutrophil-mediated inflammatory diseases and rare pulmonary disorders. Insmed is headquartered in Bridgewater, New Jersey, with a footprint across Europe and in Japan. For more information, visit www.insmed.com.
Contact:
Investors:
Bryan Dunn
Executive Director, Investor Relations
Insmed
(646) 812-4030
This email address is being protected from spambots. You need JavaScript enabled to view it.
Eleanor Barisser
Associate Director, Investor Relations
Insmed
(718) 594-5332
This email address is being protected from spambots. You need JavaScript enabled to view it.
Media:
Mandy Fahey
Executive Director, Corporate Communications
Insmed
(732) 718-3621
This email address is being protected from spambots. You need JavaScript enabled to view it.

| Last Trade: | US$195.00 |
| Daily Change: | 5.15 2.71 |
| Daily Volume: | 1,194,288 |
| Market Cap: | US$41.590B |
November 05, 2025 October 17, 2025 October 16, 2025 | |

Chimerix is on a mission to develop medicines that meaningfully improve and extend the lives of patients facing deadly diseases. The company is devoted to filling gaps in the treatment paradigm. Chimerix’s most advanced clinical-stage program is in development for H3 K27M-mutant glioma....
CLICK TO LEARN MORE
ClearPoint Neuro is a global therapy-enabling platform company providing stereotactic navigation and delivery to the brain. Applications of our ClearPoint Neuro Navigation System include electrode lead placement, placement of catheters, and biopsy. The platform has FDA clearance and is...
CLICK TO LEARN MOREEnd of content
No more pages to load